05 June 2016
: Case report
A Curious Case of Inhalation Fever Caused by Synthetic Cannabinoid
Unusual clinical course, Challenging differential diagnosis, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Thiru ChinnaduraiABCDEFG, Srijan ShresthaBDEFG, Raji AyinlaACDEFGDOI: 10.12659/AJCR.898500
Am J Case Rep 2016; 17:379-383
Abstract
BACKGROUND: This case report describes inhalation fever as an uncommon pulmonary adverse effect of synthetic cannabinoids.
CASE REPORT: A 29-year-old man was brought in for severe agitation after smoking K2, a synthetic cannabinoid. He required multiple doses of lorazepam and haloperidol for sedation. His vital signs were notable for a mild fever and tachycardia. Otherwise, the rest of his exam was unremarkable. The laboratory test was significant for leucocytosis and diffuse reticular-nodular and interstitial infiltrates on chest radiograph. Urine drug toxicology was negative. Interestingly, his symptoms and pulmonary infiltrates on the chest radiograph resolved spontaneously after 24 hours of observation.
CONCLUSIONS: This patient developed transient pulmonary infiltrates and fever following the synthetic cannabinoid inhalation, as seen in self-limiting inhalation fever. Inhalation fever as a consequence of synthetic cannabinoid has not been described previously and there is a need for further research in this field.
Keywords: Cannabinoids - adverse effects, Designer Drugs - adverse effects, Fever - chemically induced, Smoke Inhalation Injury - chemically induced
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947628
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947148
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946611
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948042
Most Viewed Current Articles
21 Jun 2024 : Case report
97,828
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,727
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
32,839
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,613
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030